Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
about
Options for empagliflozin in combination therapy in type 2 diabetes mellitusRenal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of actionSodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsSodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A ReviewImpact of sodium-glucose cotransporter 2 inhibitors on blood pressureDrug off-target effects predicted using structural analysis in the context of a metabolic network modelThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Update on developments with SGLT2 inhibitors in the management of type 2 diabetesThe influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetesPathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52-week open-label study.Short commentary on empagliflozin and its potential clinical impactContribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizinAssessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.Impact of an exercise program on acylcarnitines in obesity: a prospective controlled studyBanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusEfficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study.Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.The renal effects of SGLT2 inhibitors and a mini-review of the literature.Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin.Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.Dapagliflozin: a review on efficacy, clinical effectiveness and safety.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes.Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin.Combination therapy for type 2 diabetes: dapagliflozin plus metformin.Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials.The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
P2860
Q26745771-1DAC2221-93C7-4DAC-819B-E2890F05910CQ27027105-36CD9F2A-4588-4696-B86E-2090782D1C0BQ28074843-B81925CF-0E78-490E-8123-9F145764CA33Q28079134-68CC726C-BA4D-4847-BABA-4DA41505FB1DQ28080114-066B6F78-6567-49EF-83E1-6AD4B969C829Q28475693-29579970-6F9B-469B-BEA6-96EF913A2FE8Q30663494-07BC05DD-F4BE-41DE-A7C1-73C33E6852FCQ34198692-05D74C33-DC5F-4795-855B-D86B57022268Q34315521-77FCAEBD-5B21-497A-8332-A0832087F6F0Q34460468-55D6D3AD-8E70-477D-8C9E-488445F72FF0Q34503601-D1E37E4C-2DE5-4E74-9A6F-3C1C94392CF3Q35192198-DAA4DF2E-41D8-4AE8-A1D3-BEC79F243BF5Q35528797-EC9AEBCA-A835-44FD-AE31-0CDCB2AA5243Q35594390-F8AD4D3F-4BFE-451D-970C-AF97C9E2A4DFQ36073447-94413807-ED1D-4C24-BDA2-B2AD4D932FD6Q36175431-A8C208AE-2DD3-49D2-8408-0E7DC7F9903AQ36192546-43E3B464-ED56-4D99-B031-696F676A0FA1Q37141727-FCA9DACD-D1C1-4B96-9599-9EF5347F2E3DQ37532069-13EDBEA3-FFE3-4DFB-A007-D6696EC194B7Q37620374-18391890-57F1-44E7-98F9-B457FFF6E243Q37632127-5DAE8EC7-8594-4CC6-9A5E-5900025ED61DQ37703184-EF6791AA-372F-4F19-9C29-46CFB295ED5AQ37729725-0A660B14-F14F-49C9-A6A1-13619DFBE254Q38036770-D8293F28-5D20-43DE-A0E5-AC1F3801F164Q38057810-BA5E464A-9072-4D83-8003-714E8972A148Q38085691-A80033BA-BFDC-44B1-89AD-866078CFAFB0Q38104746-DAB7F1B2-6A5B-41C2-BA7A-6C9F9F871AA7Q38112660-7A2626FA-771C-4742-AEBA-F5C1DE528E76Q38126109-56E2E485-7758-425D-A9B4-D485207A95C8Q38164682-2B384B47-A0BB-4C0F-A038-F17E30A83395Q38196340-90C54643-0772-41AF-80A5-244631E0353AQ38205581-75323BF6-2977-4432-95EA-3B822E895AF3Q38260353-D40A15FA-163E-41F4-91B6-7956A9D2EC06Q38365957-13850131-E349-4122-A0E1-06F0A4534BEEQ38633198-442173EB-A943-4866-9D9E-790AE81407DFQ38638523-57C3151A-D961-4BC5-B156-42600E25CACDQ38783203-B17E3940-64DF-4ABC-A48E-615E077E17C3Q38863649-62D54AEC-FE33-46EC-AC2D-70C6D7417E21Q38870752-B2918406-8F1D-400D-AE3F-BB2014F7BF7AQ38906041-5C43F5B6-B7D5-4598-B789-5691D7879986
P2860
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@ast
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@en
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@nl
type
label
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@ast
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@en
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@nl
prefLabel
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@ast
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@en
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@nl
P356
P1433
P1476
Inhibition of renal glucose re ...... l in type 2 diabetes mellitus.
@en
P2093
Muhammad A Abdul-Ghani
P304
P356
10.4158/EP.14.6.782
P577
2008-09-01T00:00:00Z